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Several studies demonstrated a relevant role of polymorphisms located within the HLA-B and -C loci 
and the Killer Immunoglobulin Receptors (KIRs) 3DL1 and 3DS1 in controlling HIV-1 replication. KIRs 
are regulatory receptors expressed at the surface of NK and CD8+ T-cells that specifically bind HLA-A 
and -B alleles belonging to the Bw4 supratype and all the -C alleles expressing the C1 or C2 supratype. 
We here disclose a novel signature associated with the Elite Controller but not with the long-term 
nonprogressor status concerning 2DS activating KIRs and HLA-C2 alleles insensitive to miRNA148a 
regulation. Overall, our findings support a crucial role of NK cells in the control of HIV-1 viremia.
HIV-1 infection of CD4+ T lymphocytes and myeloid cells is characterized by a profound immunodeficiency 
leading to opportunistic infections and tumor development in most infected individuals in the absence of com-
bination antiretroviral therapy (cART). However, in a minority of people, HIV-1 infection is characterized by 
either long-term control of their CD4 T cell counts and good health for several years (long-term nonprogressors, 
LTNP) or spontaneous control of virus replication in peripheral blood (HIV- or Elite-Controllers, EC) for vari-
able periods1,2. Among the best characterized correlates of these rare (1–2% of infected individuals) conditions 
of natural control of HIV-1 disease progression, there are genetic factors, mostly associated to the HLA Class I 
loci, in addition to the heterozygous 32-bp deletion of CCR5 typical of a significant fraction of LTNP3. These 
findings have been largely interpreted and correlated with a robust CD8+ cytotoxic T cell (CTL) response keep-
ing in check the number of infected cells4. In this regard, CTL act through recognition and killing of infected 
cells mediated by specific viral peptides presented by selected Class I molecules, mostly belonging to the HLA-B 
locus4. Moreover, evidence has emerged on the epistatic association between the HLA-B supratype Bw4 and the 
Killer Immunoglobulin–like receptors (KIRs) 3DL1/DS1 locus in the beneficial responses to HIV-15,6. Indeed, 
both innate and adaptive cellular immunity share HLA class I ligands7,8 and the KIR multigene family9,10 as fine 
regulators of their activity.
KIRs are encoded in humans by at least 15 distinct polymorphic gene loci located in a region of 150–200 kb 
of the leukocyte receptor complex (LRC) on human chromosome 19q13.47,11 and display either inhibitory (L) or 
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activating (S) functions10,12. They are inherited as different haplotypes, resulting in a centromeric and a telomeric 
KIR profile that varies in number and composition of genes12,13. The majority of these receptors bind to different 
groups of HLA class I molecules14 encoded by genes located on chromosome 6. Interestingly, evolution drove at 
least 5 KIRs to recognize HLA-C alleles, the most recently developed forms amongst HLA molecules15.
The involvement of other HLA loci, mainly HLA-C, in HIV-1 control has been long questioned1,16, being 
dismissed as a simple carryover of the existing linkage disequilibrium (LD) with some protective HLA-B alleles, 
such as B57:0117. Only in recent years, several genetic and functional experimental studies strongly supported an 
independent involvement of HLA-C molecules in HIV-1 infection outcomes18,19. Studies based on genome wide 
association analyses (GWAS) proved that a genetic variant rs9264942 C/T located 35 Kb upstream of the HLA-C 
locus was associated with control of viremia20,21, slower disease progression22, and the levels of HLA-C cell surface 
expression in caucasoid populations23. Subsequently, the causal variant responsible for these associations was 
identified as a Single Nucleotide Polymorphism (SNP) (rs67384697G/del) that maps in the 3′ UTR of HLA-C 
alleles, and affects the binding of the microRNA Hsa-miR-148a24. This SNP was shown to partially influence cell 
surface expression of HLA-C with weakly expressed alleles possessing an intact miR148a binding site (263 G) and 
highly expressed alleles having a deletion in the site (263del), thus escaping the regulation by that microRNA24.
Independent evidence for a causal effect of HLA-C expression on HIV-1 control was provided by the direct 
relation between the frequency of escape mutations in predicted HLA-C epitopes and viral load25,26 and by the 
strong positive correlation between the frequency of HLA-C peptide-restricted CTL responses and HLA-C 
expression26. Noteworthy, HLA-C molecules insensitive to the HIV-1 escape strategy mediated by the viral pro-
tein nef can be downmodulated by some variants of the VPu accessory molecules1,27,28.
In this study, we analyzed chromosome 6 genetic markers in combination with the assessment of the KIR 
genotype in a well characterized cohort of Italian EC and LTNP. Our results provide evidence that a complex 
genotype displaying high expression of HLA-C alleles belonging to the C2 group and their KIR 2DS receptors 
ligands is a hallmark of the EC but not of the LTNP status. These findings suggest a novel role for activating 2DS 
KIRs expressed on both NK and CD8+ T-cells in the control of HIV-1 viremia.
Results
The HLA Class I region and KIR genes influence the natural course of HIV-1 infection. An 
explorative multiple correspondence analysis of selected chromosome 6 polymorphisms within the HLA-B and - 
C class I region and of KIR genes was conducted independently to verify whether combinations of the selected 
chromosome 6 and 19 markers could discriminate between the two best characterized cohorts of natural control-
ler of HIV-1 infection, i.e. EC and LTNP, in comparison to HIV-1 Progressors (P) or HIV-1 seronegative healthy 
blood donors (HD). The presence of activating KIR genes, namely 3DS1, 2DS1 and 2DS5 on chromosome 19 
(Fig. 1A) clearly distinguished the 40 EC (lower right quadrant) from the 111 HD (upper left quadrant) and to 
some extent from the189 HIV P (lower left quadrant), whereas the 39 LTNP segregated in an intermediate posi-
tion between EC and P.
Both EC and LTNP segregated independently from P and HD for chromosome 6-associated markers (Fig. 1B), 
that included homozygosity of SNP rs9264942C, commonly termed − 35C, and of SNP rs67384697del (263del) as 
well as the presence of HLA-B alleles both belonging to the Bw4-I80 supratype.
As both groups of HIV-controllers segregated in close proximity they were also jointly analysed and com-
pared with P (Supplemental Fig. 1), confirming the strong association with the homozygous status for both 
HLA-C-associated SNPs and the presence of Bw4-I80 alleles. As expected, HD segregated with P (Fig. 1A,B), the 
latter representing the natural evolution of HIV infection in most (≥ 95%) individuals.
Distinct sets of KIRs and HLA genes are involved in HIV-1 disease control. The study of the uni-
variate associations (Fig. 2A) between the status of natural HIV-1 controllers, encompassing both EC and LTNP, 
and KIR genes confirmed a role for the 3DS1 gene (p < 0.05), but also showed a strong association (p < 0.01) with 
another activating KIRs, the 2DS3 gene. Interestingly, when the two groups of controllers were independently 
analysed and compared with P (Fig. 2B,C), EC showed a different behaviour from LTNP as suggested by the 
multiple correspondence analysis. The telomeric B haplotype activating KIRs 3DS1 and 2DS1 increased the odds 
of being an EC (OR = 2.25, p = 0.02 and OR = 2.10, p = 0.03, respectively), whereas the other 2DS3/5 activating 
KIRs were of borderline statistical significance (OR = 1.98, p = 0.055) (Fig. 2B). Conversely, only the 2DS3 gene 
was significantly associated with the LTNP status (OR = 2.2, p = 0.03) (Fig. 2C).
We next investigated the allelic association between HLA genes and the HIV-1controller status (Fig. 3). Both 
HLA-C-associated SNPs and the Bw4-I80 supratype were significantly associated with elite controller status, 
while the HLA C1/C2 supratype was not associated (Fig. 3A). Of note, EC and LTNP were characterized by an 
inverse pattern of the 263del and the Bw4-I80 supratype, the former being the strongest marker of the EC status 
and the latter the weakest with borderline significance (Fig. 3B), whereas this pattern was switched in LTNP 
(Fig. 3C). In addition, the effect of allele dosage for these three significant markers was investigated (Fig. 3D–F). 
Homozygosity for 263del, − 35 C and the presence of two HLA-B alleles carrying the Bw4-I80 epitope signifi-
cantly increased the odds of being a HIV-1 controller compared to heterozygosity (Fig. 3D; p for trend < 0.01 or 
less). Of interest, both HLA-C-associated SNPs showed the best association (− 35 C/C OR = 6.2, CI = 2.6–14.6; 
263 del/del OR = 4.9, CI = 2.1–11.1), whereas the effect of Bw4 I80/I80 was weaker (OR = 3.1, CI = 1.3–7.4).
A difference was noted again between ECs and LTNPs (Fig. 3E,F): the allele dosage effect of Bw4-I80 was 
observed only in LTNPs where the odds conferred by Bw4-I80/I80 were higher than those associated with the 
Bw4-I80/others genotypes (OR = 3.9, CI = 1.4–10.9, OR = 1.9, CI = 0.85–4.2, respectively, p for trend < 0.01).
HIV-controllers are characterized by a complex chromosome 6 haplotype. We tested whether 
the overall haplotype variation among the markers selected on chromosome 6 influenced the HIV-1 controller 
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phenotype. As HLA genes are located at adjacent loci and are presumed to exhibit epistasis with each other or 
with other genes, we assessed the degree of LD in HD (see Material and Methods) matched for ethnicity and geo-
graphical origin with our HIV-1 infected groups. Only the HLA-C-related SNPs (Supplemental Table 1) showed 
a moderate degree of LD (D’ = 0.62). The haplotype containing the three significant alleles in the univariate anal-
yses (263del, − 35C, Bw4-I80) clearly increased the odds of being either EC (OR = 3.5, p = 0.0013) or LTNPs 
(OR = 3.5, p = 0.0025) (Table 1).
Surprisingly, the addition of the C2 supratype strongly reinforced the haplotypic association with the status 
of EC (OR = 6.1, p = 0.00167) but not of LTNP (OR = 3.9, p = 0.0136). In contrast, a haplotype containing the 
C1 marker was neither significantly associated with the status of ECs nor of LTNPs. These findings suggest that 
the presence of the HLA-C2 alleles carrying a miRNA 148a/b deleted site may play a key role in determining the 
EC status.
EC are identified by a unique genetic configuration. We assessed the distribution of each signifi-
cant KIR gene in HIV-1 controllers and P (Table 2), conditioning on the presence/absence of the described four 
marker-haplotype (Haplo4+ /Haplo4−) on chromosome 6. Among Haplo4+ carriers only haplotype B activating 
KIRs (3DS1, 2DS5, 2DS1, 2DS3) were significantly associated with the EC status. We extended the previously 
described association between 3DS1 and the presence of the Bw4-I80 allele5 to ECHaplo4+ carriers, but, more 
importantly we described an even stronger association between activating 2DS genes and the haplotype featuring 
C2 alleles insensitive to the miRNA 148a/b regulation that could be considered a hallmark of EC (Table 2). In 
contrast, LTNP did not show a relevant association with any of the activating KIRs beside a modest association 
with the B centromeric 2DS3 gene in the the Haplo4− individuals (Table 2).
Finally, the expression of the activating 2DS1 and 2DS5 molecules was assessed by cell surface immunos-
taining of circulating resting CD3+ CD8+ T lymphocytes (Fig. 4A–F) and CD3-CD16+ CD56dim NK cells 
Figure 1. Principal component analysis of genetic markers on chromosome 19 (A) or 6 (B). Distinct groups of 
HIV-1 infected individuals and HIV-1 negative donors are indicated with a black filled box (E: Elite Controller, 
L: Long Term Non Progressor, P: Progressor, H: Healthy HIV-1 negative donors). (A) KIR genotypes are shown 
by black filled circles (p: positive, n: negative). (B) HLA-C, HLA-Bw4-I80, − 35 SNPs and miRNA148a SNPs 
homozygous and- heterozygous genotypes are indicated.
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(Fig. 4A’–F’) in six EC. All three ECs characterized by the 2DL1+ 2DS1+ 2DS5+ genotype presented both 2DS1 
and 2DS5 expressing NK populations (Fig. 4A’–F’) which were undetectable in the three EC carrying the 2DL1+ 
2DS1–2DS5- genotype (Fig. 4D’–F’). Only one individual carrying the 2DL1+ 2DS1+ 2DS5+ genotype pre-
sented 2DS1 and 2DS5 positive populations within CD8+ T lymphocytes (Fig. 4A).
Discussion
This paper describes an in-depth combined analysis of chromosome 6 genetic markers with the complete KIR 
genotype configuration revealing, for the first time, a crucial role of 2DS KIR receptors and their HLA-C2 lig-
ands, insensitive to miRNA148a regulation, in the control of HIV viremia naturally occurring in EC of caucasoid 
origin.
By exploiting two different groups of HIV-1 controllers, namely 40 EC and 39 LTNP with persistent and 
detectable plasma viral load, we revealed a distinct role of Bw4-I80 HLA-B expressing alleles and miRNA148a 
insensitive HLA-C alleles in HIV-1 control, pin-pointing a novel association of the 2DS KIRs with the EC status.
All the statistical approaches conducted separately on both groups of HIV-controllers indicated substantial 
differences between EC and LTNP. Indeed epidemiological studies conducted on large populations of HIV-1 
infected individuals29 indicated that these two phenotypes of HIV-1 controllers did not overlap, with extremely 
few individuals showing features of both EC and LTNP. However, the genetic or immunologic correlates distin-
guishing LTNP and EC have remained elusive thus far.
Figure 2. Effect of chromosome 19 genetic polymorphisms on lack of HIV disease progression. The 
estimate of the risk was calculated comparing EC and/or LTNP vs HIV-1+ P. Panels (A–C) show the odds ratio 
and 95% confidence interval considering an additive allelic genetic model. The asterisk indicates bonferroni 
corrected significant p-values: *p < 0.05, **p < 0.01.
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The multiple correspondence and logistic regression analyses performed on the KIR genotyping data set indi-
cated a significant association between the 3DS and 2DS loci and EC. Interestingly, the cumulative analysis of 
both groups as HIV-controllers confirmed a role only for the KIR3DS1 locus, as previously described5.
Furthermore, consistent differences were found between the effects of HLA-C associated SNPs and the 
Bw4-I80 supratype. Of interest, opposite effects are shown by the 263del and the Bw4-I80 polymorphisms in EC 
and LTNP. Indeed, the analysis of the allele dosage suggested a clear advantage of 263del homozygosity in defining 
the EC status, whereas the presence of both HLA-B alleles carrying the Bw4-I80 supratype was not significant. In 
contrast, the presence of both HLA-Bw4-I80 expressing alleles was advantageous for LTNP, whereas homozygo-
sity for 263del is the least powerful marker in defining the LTNP status.
These observations underscored a major role of HLA-C alleles escaping miRNA 148a regulation in EC and 
a primary role of HLA-B alleles carrying the Bw4-I80 epitope in LTNP. Intriguingly, the -35 C/C polymorphism 
identified by GWAS studies20,21 was revealed to be the strongest predictor either for HIV-controllers or LTNP 
status. Taken together, these findings suggest that the -35 SNP could serve as an associated marker for both the 
263del and HLA-B allele belonging to the Bw4-I80 supratype. Thus, consistent with its chromosome 6 location 
between the HLA-B and -C loci, the -35 SNP may flag the HLA-B and -C driven T-cell response of both LTNP and 
EC1,30 whereas additional mechanisms for HIV-control linked to HLA-C expression are likely present only in EC.
The presence of multiple immune mediated mechanisms responsible for HIV-control in EC and LTNP is 
further underlined using haplotypic models to test interactions of chromosome 6-associated markers in defin-
ing the EC or LTNP status. The increasing odds ratios obtained by adding progressively each significant marker 
(-35 C/C, 263del and Bw4-I80) underlines the presence of at least one shared mechanism responsible for 
HIV-control. On the other hand, the strong effect caused by the addition of the C2, but not of the C1 supratype, 
Figure 3. Effect of chromosome 6 genetic polymorphisms on HIV control. The estimate of the risk was 
calculated comparing EC and/or LTNP vs HIV-1 + P. Panels (A–C) show the odds ratio and 95% confidence 
interval considering an additive allelic genetic model. The asterisk indicates bonferroni corrected significant 
p-values (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Panels (D–F) show the odds ratio and 95% 
confidence intervals considering a genotypic genetic model (presence of two copies or one copy of the risk 
allele vs no copies). The asterisk indicate chi-square test for trend p-value for the statistically significant 
polymorphism:(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
www.nature.com/scientificreports/
6Scientific RepoRts | 7:42470 | DOI: 10.1038/srep42470
indicates an independent contribution of C2 alleles escaping miRNA148a regulation in defining the EC, but not 
the LTNP, linking, for the first time, this HLA-C-related peculiarity to HIV-control.
Finally, the stratified analysis that combined activating KIR loci and the best protective chromosome 6 haplo-
type (Haplo 4) confirmed a role of both the 3DS1/Bw4-I80 and 2DS/C2 263del pairs in defining again the EC sta-
tus. Thus, only EC display a genotype suggestive for epistasis between activating KIRs and their best HLA-B and 
-C2 ligands. Therefore, NK cells of individuals displaying a complete KIR B haplotype, including both 3DS1 and 
multiple 2DS genes13 and their specific HLA-B and -C ligands, might be facilitated in overcoming KIR-mediated 
inhibitory signals, thus contributing to direct recognition and faster clearance of HIV-infected cells. Indeed, 
the 2DS1 receptor31,32 and, more recently, the 3DS1 molecule33 were shown to bind HLA-C2 and HLA-Bw4-I80 
alleles, respectively, with a weak interaction. In this regard, the selective association with the C2 alleles displaying 
a higher surface expression14,24 may compensate for the lower binding affinity of the 2DS1 molecule. In addi-
tion, the binding of 3DS1 to the HLAB-57:01 molecule (a Bw4-I80 allele) is strongly influenced by the type 
of peptide loaded in the MHC binding cleft33 supporting a model whereby changes in the peptide repertoire 
due to viral infection trigger the activating KIR engagement and NK-cell mediated elimination of infected cells. 
Although, the binding of HLA-C alleles has never been demonstrated for the 2DS3/5 receptors32, a similar pep-
tide dependence could be hypothesized also for these receptors which are closely related to the HLA-C2 specific 
2DL1/S1 molecules (Supplemental Figure 2A). Notably, the neighbour-joining tree representing the similarity 
of the KIRs amino acidic residues involved in the HLA-C/peptide interaction according to the known crystal-
lographic structures showed that the 2DS3/5 receptors are the closest molecules to the 2DL1/2DS1 receptors 
(Supplemental Figure 2B).
Indeed, these two KIR molecules share 17/18 of the amino acidic residues present in the interface between 
HLA-C and 2DL molecules. Noteworthy, the unique amino acidic change (M44T) featured by both 2DS3 and 
2DS5 is compatible (Supplemental Figure 3) with the retainment of HLA-C binding involving the side chains 
of neighbouring amino acids (Arg 79 and/or Lys 80) in hydrogen bond interactions with the Thr 44 side chain. 
Haplotypiccombination
EC (N = 40) versus 
Progressor (N = 185)
LTNP (N = 39) versus 
Progressor (N = 185)
OR (95% CI) P OR (95% CI) P
rs67384697 and rs9264642 2.8 (1.6–4.9) 0.00024 2.5 (1.4–4.5) 0.00131
rs67384697 and Bw4–I80 2.4 (1.3–4.3) 0.00546 2.3 (1.2–4.2) 0.00938
rs9264642 and Bw4–I80 3.1 (1.6–6.1) 0.00027 2.8 (1.4–5.6) 0.00315
rs67384697, rs9264642 and 
Bw4–I80 3.5 (1.6–7.4) 0.00130 3.5 (1.6–7.9) 0.00246
rs67384697, rs9264642, 
Bw4–I80 and HLA–C2 6.1 (2.0–18.1) 0.00167 3.9 (1.3–11.4) 0.0136
rs67384697, rs9264642, 
Bw4–I80 and HLA–C1 2.5 (0.8–7.6) 0.107 2.8 (0.9–8.9) 0.083
Table 1.  Haplotypic combination of chromosome 6 markers in different populations of HIV-controllers 
and Progressors.
KIRs
EC (N = 40) versus 
Progressor (N = 185)
LTNPs (N = 39) versus 
Progressor (N = 185)
ORMH (95% CI) P§ ORMH (95% CI) P§
3DS1
 Haplo4+ 6.82 (1.56–29.87) 0.0031 2.25 (0.55–9.13) 0.2436
 Haplo4− 1.36 (0.56–3.35) 0.4966 1.74 (0.74–4.09) 0.2019
2DS5
 Haplo4+ 4.79 (1.18–19.42) 0.0153 1.15 (0.23–5.65) 0.8633
 Haplo4− 1.38 (0.55–3.46) 0.4846 0.94 (0.38–2.33) 0.8957
2DS1
 Haplo4+ 6.82 (1.56–29.87) 0.0031 1.64 (0.40–6.70) 0.4862
 Haplo4− 1.26 (0.51–3.09) 0.6116 1.16 (0.50–2.72) 0.7257
2DS4-CDS
 Haplo4+ 3.14 (0.84–11.72) 0.0719 0.94 (0.20–4.51) 0.9412
 Haplo4− 0.94 (0.37–2.38) 0.8952 2.09 (0.88–4.96) 0.0863
2DS3
 Haplo4+ 7.67 (1.69–34.82) 0.0018 2.40 (0.55–10.50) 0.2315
 Haplo4− 0.93 (0.36–2.44) 0.8879 2.55 (1.07–6.08) 0.0293
Table 2.  Logistic multivariate analysis of KIRs in EC or LTNP individuals versus Progressors, in the 
presence (Haplo4+) or absence (Haplo4−) of the chromosome 6 aplotype. ORMH: Mantel–Haenszel Odds 
Ratio; §P:P value refers to the Mantel–Haenszel Chi–square test.
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Along this line, replacement of the Met 44 with Thr in 2DL1*003 molecules does not abrogate C2 specificity 
retaining 50% of avidity34. Our findings support the view that a functional combination of a complex HLA-B 
and -C haplotype with a KIR B haplotype containing a full array of activating KIRs represents a major mecha-
nism of HIV-control in EC, as it is shared by almost 40% of individuals. Thus, it is likely that HLA-C molecules 
may participate directly in the immune response against HIV-1 triggered by activating KIR mediated NK-cell 
responses and a CD8 T-cell selective pressure on the virus. This association was independent from the time-span 
of HIV-seropositivity and whether the infection occurred before or after the introduction of cART. Unfortunately, 
given the Italian origins of our cohort of HIV-controllers it was not possible to evaluate whether this complex 
genotype is featured also by Sub-saharian African populations, known to be characterized by different allelic 
forms and distribution of activating KIRs genes35.
Notably, the present data show that in EC the presence of an activating KIR genotype correspond to their cell 
surface expression mainly on NK cells, supporting a predominantly direct NK-cell mediated mechanism of HIV 
control, with downstream editing of CD8+ T cell responses.
Although the limited number of individual tested for KIR expression does not allow us to draw a definitive 
conclusion, these findings suggest a crucial involvement of NK cells in the immune control of HIV-1-viremia 
through a network of coexpressed 2DS/3DS1 molecules. These data are in line with the distinctive persistence of 
effective induction of activating natural citotoxicity receptors in the vast majority of HIV-controllers36.
The engagement of both NCRs and, more importantly, the 2DS/3DS1 KIRs receptors in individuals carrying a 
complex HLA haplotype that combines both HLA-Bw4-I80 and C2 alleles escaping miRNA 148a regulation will 
be crucial in mounting a quick antiviral response that limits and maintain under control the viral reservoire of 
infected cells.
Methods
Patients. Genomic DNA was extracted from circulating mononuclear cells derived from a group of 79 HIV–
controllers belonging to Caucasoid ethnicity encompassing 40 Elite Controllers (EC) featuring one or more yrs of 
HIV–1 plasma RNA load < 50 copies/ml (median = 14; 1–3° IQR = 10–21) and 39 Long Term Non Progressors 
(LTNP) with a documented history of HIV–1 seropositivity > 9 yrs (median = 17; 1–3° IQR = 13–22). A control 
Figure 4. Surface expression of KIR 2DS1 and 2DS5 on circulating CD8 and NK-cells. Resting PBMCs are 
gated according to anti-CD3 and anti-CD8 mAbs (CD3+ CD8+ T lymphocytes: panels A–F) or anti-CD3, 
anti-CD16 and anti-CD56 mAbs (CD3-,CD16+ CD56dim NK lymphocytes: panels A’–F’). Zebra plots of 
PBMCs stained with MAbs reacting only with the 2DL1/2DS5 (y axes) or with the 2DL1/2DS1 molecules  
(x axes) in EC positive (panels A–C and A’–C’) or negative (panels D-F and D’-F’) for the 2DS1 and 2DS5 gene 
are shown.
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group of 189 HIV–1 Progressors (P) included 93 individuals with immunological reconstitution following 
cART, 61 ART–naïve viremic individuals with a documented history of HIV–seropositivity < 7 yrs (median = 3; 
1–3° IQR = 1–6) requiring the introduction of cART and 35 individuals with primary HIV-infections or recent 
seroconverters.
Finally, genomic DNA samples derived from 111 HIV–seronegative healthy blood donors were utilized for 
conducting only the multiple components and the LD analysis. Demographic and laboratory features of these 
populations are summarized in Supplemental Table 1.
KIR genotyping, HLA and SNPs genotyping. KIR genotyping was performed by a modification of a pub-
lished SSP–PCR system37. HLA supratyping used a published pyrosequencing approach38–40 that relies on a nested 
PCR protocol where the first amplification with a separate set of primers amplifies all HLA-B or HLA-C alleles, 
whereas a second PCR reaction is used to amplify the fragment subjected to pyrosequencing, distinguishing Bw4 
(Iso/Thr)80 from Bw6 HLA–B alleles and Ser77/Asn80 or Asn77/Lys80 HLA–C alleles representing C1 or C2 KIR lig-
ands, respectively. The HLA supratyping data were independently verified using classical HLA typing approaches 
in 50% of the cases with a particular attention to samples that resulted identical for HLA-B and -C supratyping38.
The single nucleotide polymorphism rs9264942 C/T (-35) has been analyzed using quantitative pyrosequenc-
ing selecting primers outside of the polymorphic regions. Sequencing has been performed with the 5′ TCA GAA 
AGT CCC ACA GT3′ oligonucleotide following the nucleotide dispensation order: TGCT[A/G]CAG and pol-
ymorphism is evaluated in the anti-sense orientation. The same method was adopted to analyze the rs67384697 
(G/deletion) polymorphism centered at the residue–263 of the 3′ UTR region of HLA–C alleles41. SNPs analysis of 
homozygous samples was repeated at least twice.
Monoclonal Antibodies (mAb) and cell surface staining. Anti–CD8 (clone SFCI21Thy2D3) and anti–
CD3 (clone SK7) mAbs were purchased from Beckman Coulter; anti–CD16 (clone 3G8) and anti–CD56 (clone 
B159) mAbs were from Becton Dickinson. The KIR receptors 2DL1/2DS1 were detected using the mAb 11PB642 
(MiltenyiBiotec), whereas mAb 143211 (R&D Systems) was used to detect the 2DL1/2DS5 molecules43. LIVE/
DEAD fixable Aqua dead cell stain kit was purchased from Invitrogen.
The samples were acquired with a Gallios flow cytometer (Beckman Coulter, Inc.) and analyzed using 
FlowJo version 8.8.7 (Tree Star). Lymphocytes were gated on a forward scatter versus side scatter area using 
pseudo-colour dot plot and dead cells were removed according to positive Aqua stain. CD8+ T–cells were identi-
fied within the CD3+ -lymphocytes, whereas NK cells (CD16+ CD56dim) were gated within the CD3− cells. Cells 
stained by the KIR–specific mAbs binding KIR2DL1/2DS1 (mAb 11PB6) and KIR2DL1/2DS5 (MAb 143211) 
were plotted on the x–axis and y–axis respectively, allowing the discrimination between 2DL1, 2DS1 and 2DS5 
KIR positive cells.
Statistics. A power analysis was employed to calculate the dimension of the HIV-controllers and Progressors 
groups. Four HIV progressors were excluded from the analysis due to insufficient sample material that did not 
allow the complete genetic marker testing. The statistical power of 80% was achieved for searching allelic Odds 
Ratios (OR) ≥ 2, considering a type 1 error level of 5% and minor allele frequencies (MAF) between 20% and 
40% of the above described groups of HIV–1 infected individuals. To assess the association between each genetic 
marker and HIV–controller status (EC and/or LTNP) we performed univariate allelic Pearson chi–square or 
Fisher exact tests when appropriate and applied Bonferroni correction considering the number of markers tested 
for chromosome 6 and 19; moreover, the Cochran–Armitage trend test was applied to evaluate a possible additive 
dose-response effect of the considered risk alleles of chromosome 6. Adjusted Odds Ratio (OR) with 95% confi-
dence intervals (95% CI) were derived and used as the measure of effect.
The global association of the EC or LTNP status with the significant chromosome 6 or 19 genetic markers was 
explored by multiple correspondence analysis44. To test whether the overall haplotype variation of the chromo-
some 6 HLA markers influences the HIV–controller status, we performed a Likelihood Ratio (LR) based omnibus 
association test, considering specific haplotypes. In addition, we tested whether a single marker had an independ-
ent effect (independent of the haplotypic effects formed by the remaining markers) or it was associated to EC 
and/or LTNP status due to Linkage Disequilibrium (LD), performing conditional LR–based tests and asymptotic 
p-values. To take in account the possible role of a chromosome 6 risk haplotype, we carried out a stratified anal-
ysis on each chromosome 19 significant marker. The Mantel–Haenszel method provided pooled and separated 
odds ratio for each strata (presence/absence of the chromosome 6 haplotype). The allele frequencies in controls 
were examined to detect any significant deviation from the Hardy–Weinberg Equilibrium (HWE) using a good-
ness of fit Chi–square test. LD was calculated using HAPLOVIEW software. Statistical analyses were performed 
using Plink 1.0845, XLstat (Version 2, Addinsoft) and Stata 11 (Stata Corporation, College Station, TX, USA).
Study approval. All the experiments were performed in accordance with relevant guidelines and regulations 
and all participants gave a written informed consent to the study protocol prior to inclusion in the study. This 
study was approved by the IRCCS AOU San Martino-IST Genoa n51/09, ALS 2 n°10/2011, IRCCS San Raffaele 
Hospital, Milan (EUDRACT numbers 2003-P-001678/14; 2008-006287-11;2008-007004-29) and by L Sacco 
Hospital Milan (ELVIS 2008/419) ethical Commitees.
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